Abstract: The mechanism of cisplatin resistance in ovarian cancer is complex. It is related to the protein concerned with many kinds of enzymes: a) The ascension of Glutathione (GSH) and Glutathione S transferase (GST), both of which can accelerate degeneration of the anticancer drugs and can bring about rapid reduction of medicamentous accumulation in the target site. Moreover, GST may also quicken excretion of the anti-cancer drugs. b) Ascension of the lung resistance-related protein (LRP), which may prevent the drugs taking the cell nucleus as its target from entering the cell nucleus through the nuclear pore, cause the medicine in the cytoplasm to enter the transport pouch and can be excreted out of the cells by exocytosis. c) Analysis of reduction of the situ isomerase Ⅱɑ (topoisomeraseⅡɑ, TopoⅡɑ): TopoⅡcan mediate breakage of the DNA chain, thus causing the apoptosis. d) Ascension of the metallothionein (MTN), which may eliminate the free radical and the superoxide free radical, with a deintoxication of the heavy metals, esp. for the platinums. In addition, the mechanism of cisplatin-resistance is possibly related with the ascension of the multidrug resistance-associated protein (MRP) too, and the P-GP protein with function of the medicamentous drug pump. In brief, the mechanism of drug resistance is complicated. A variety of mechanisms of the drug resistance might simultaneously exist in one drug resistance cell. To seek an index which can objectively and all-roundly reflect the resistance has become the pending issue for workers of the gynecological oncology.